Sequential chemotherapy for advanced epithelial ovarian cancer: platinum combination cytoreduction followed by cyclophosphamide consolidation.
dc.contributor.author | Lawton, Frank | |
dc.contributor.author | Blackledge, G | |
dc.contributor.author | Buckley, H | |
dc.contributor.author | Johnson, Richard J | |
dc.contributor.author | Kelly, K | |
dc.contributor.author | Crowther, Derek | |
dc.date.accessioned | 2010-12-02T11:21:55Z | |
dc.date.available | 2010-12-02T11:21:55Z | |
dc.date.issued | 1985-12 | |
dc.identifier.citation | Sequential chemotherapy for advanced epithelial ovarian cancer: platinum combination cytoreduction followed by cyclophosphamide consolidation. 1985, 21 (12):1479-83 Eur J Cancer Clin Oncol | en |
dc.identifier.issn | 0277-5379 | |
dc.identifier.pmid | 2420603 | |
dc.identifier.doi | 10.1016/0277-5379(85)90242-1 | |
dc.identifier.uri | http://hdl.handle.net/10541/116916 | |
dc.description.abstract | Thirty-six women with advanced epithelial ovarian cancer were treated with a combination of cisplatin, vinblastine and bleomycin followed by a consolidation regimen of intravenous cyclophosphamide. There was a 53% response rate in previously untreated patients with 25% complete clinical remissions. Sixteen per cent of previously untreated patients remain in a complete clinical remission of greater than 3 yr duration. In a multivariate analysis bulk tumor residuum was not a significant adverse factor in terms of survival, suggesting that intensive chemical cytoreduction followed by non-cross-resistant consolidation may overcome such prognostic variables. | |
dc.language.iso | en | en |
dc.subject | Anticancerous Combined Chemotherapy Protocols | en |
dc.subject | Ovarian Cancer | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Bleomycin | |
dc.subject.mesh | Cisplatin | |
dc.subject.mesh | Cyclophosphamide | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Ovarian Neoplasms | |
dc.subject.mesh | Vinblastine | |
dc.title | Sequential chemotherapy for advanced epithelial ovarian cancer: platinum combination cytoreduction followed by cyclophosphamide consolidation. | en |
dc.type | Article | en |
dc.contributor.department | Cancer Research Campaign, Department of Medical Oncology and Department of Radiology, Christie Hospital and Holt Radium Institute, Wilmslow Rd., Manchester UK | en |
dc.identifier.journal | European Journal of Cancer & Clinical Oncology | en |
html.description.abstract | Thirty-six women with advanced epithelial ovarian cancer were treated with a combination of cisplatin, vinblastine and bleomycin followed by a consolidation regimen of intravenous cyclophosphamide. There was a 53% response rate in previously untreated patients with 25% complete clinical remissions. Sixteen per cent of previously untreated patients remain in a complete clinical remission of greater than 3 yr duration. In a multivariate analysis bulk tumor residuum was not a significant adverse factor in terms of survival, suggesting that intensive chemical cytoreduction followed by non-cross-resistant consolidation may overcome such prognostic variables. |